Mostrando 10 resultados de: 55
Filtros aplicados
Publisher
Pharmacogenomics(17)
Pharmacogenomics Journal(6)
Drug Metabolism and Drug Interactions(5)
Drug Metabolism and Personalized Therapy(5)
European Journal of Clinical Pharmacology(3)
Área temáticas
Farmacología y terapéutica(43)
Enfermedades(21)
Medicina y salud(17)
Fisiología humana(12)
Bioquímica(10)
Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype
ArticleAbstract: To investigate the importance of genetic factors for the regulation of haloperidol metabolism, we stPalabras claves:debrisoquine, Haloperidol, humans, pharmacogeneticsAutores:Adrián LLerena, Alm C., Bertilsson L., Dahl M.L., Ekqvist B.Fuentes:scopusHaloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: Increased plasma levels of the reduced metabolite in poor metabolizers
ArticleAbstract: We have previously shown that the disposition of haloperidol is decreased in poor (PM) compared to ePalabras claves:debrisoquine, humans, pharmacogenetics, Reduced haloperidolAutores:Adrián LLerena, Bertilsson L., Dahl M.L., Ekqvist B.Fuentes:scopusEvaluating a newly developed pharmacogenetic array: Screening in a Spanish population
ArticleAbstract: Aims: How genes affect the response in a patient to a given medication is still poorly understood; tPalabras claves:accuracy, CYP2D6, PHARMAChip array ®, pharmacogenetics, sensitivity, SLC6A4, Specificity, successful genotyping rateAutores:Abad-Santos F., Adrián LLerena, Almoguera B., Ayuso C., Dal-Ré R., Dorado P., Fernandez-Piqueras J., Gomez-Dominguez B., Lopez-Rodriguez R., Riveiro-Alvarez R., Vaquero-Lorenzo C.Fuentes:scopusFrequency of S-mephenytoin hydroxylation deficiency in 373 spanish subjects compared to other Caucasian populations
ArticleAbstract: We have investigated the prevalence of poor metabolisers (PM) of S-mephenytoin in 373 unrelated, heaPalabras claves:caucasian, drug metabolism, Mephenytoin, pharmacogenetics, Phenotype, polymorphismAutores:Adrián LLerena, Benitez Rodriguez J., Bertilsson L., Carrillo J.A., Reviriego J., Valdivielso M.J.Fuentes:scopusGenetic variability of CYP2C9∗2 and CYP2C9∗3 in seven indigenous groups from Mexico
ArticleAbstract: Aim: CYP2C9 is one of the major drug metabolizing enzymes, however, little is known about polymorphiPalabras claves:allele frequency, CYP2C9, hypoglycemic therapy, Mexican indigenous, pharmacogenetics, polymorphismAutores:Adrián LLerena, García-Rodríguez M., Granados-Silvestre M., Menjívar M., Ortiz-López M.G., Peña-Espinoza B., Rivera-Santiago C., Sánchez-Pozos K.Fuentes:scopusDevelopment of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes
ArticleAbstract: Background: Losartan is metabolized to losartan carboxylic acid (E-3174) by the polymorphic cytochroPalabras claves:CYP2C9*Hispanics, LOSARTÁN, pharmacogenetics, PhenotypeAutores:Adrián LLerena, de Andrés F., Dorado P., Machín E., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusCurrent insights into interethnic variability in testicular cancers: Population pharmacogenetics, clinical trials, genetic basis of chemotherapyinduced toxicities and molecular signal transduction
ReviewAbstract: Testicular cancer is an aggressive malignancy with a rising incidence rate across the globe. TesticuPalabras claves:clinical trials, ethnicity, Molecular aspects, pharmacogenetics, Pharmacogenomics, population pharmacogenetics, Precision Medicine, signal transduction, Testicular cancer, Testicular seminoma, Toxicity, Variant polymorphismAutores:Adrián LLerena, de Andrés F., Kothari R., Mishra A., Nair S., Vasistha A.Fuentes:scopusChallenges and Opportunities for Clinical Pharmacogenetic Research Studies in Resource-limited Settings: Conclusions From the Council for International Organizations of Medical Sciences–Ibero-American Network of Pharmacogenetics and Pharmacogenomics Meeting
ArticleAbstract: Purpose: The symposium Health and Medicines in Indigenous Populations of America was organized by thPalabras claves:CIOMS-RIBEF, clinical research, pharmacogenetics, resource-limited settingsAutores:Adrián LLerena, Diwakar S., Enrique Terán, Galaviz-Hernandez C., Gil J.P., Isabel Hernández, Lara-Riegos J., Molina-Guarneros J.A., Moya G.E., Nair S., Penãs-Lledó E.M., Rägo L., Ramírez-Roa R., Sosa-Macías M.G., Tarazona-Santos E.M., Verde I.Fuentes:googlescopusCharacterization of CYP2D6 genotypes and metabolic profiles in the Portuguese population: Pharmacogenetic implications
ArticleAbstract: CYP2D6 codes for a protein that is vastly involved in the metabolism of various substances. This genPalabras claves:CYP2D6, CYP450, Metabolic profile, pharmacogenetics, Pharmacogenomics, polymorphism, Portuguese populationAutores:Adrián LLerena, Albuquerque J., Grazina M., Naranjo M.E.G., Ribeiro C.Fuentes:scopusClinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs
ReviewAbstract: CYP2D6 is described as the most relevant enzyme in the metabolism of many antipsychotic drugs. Its cPalabras claves:Antipsychotic drugs, CYP2D6, pharmacogenetics, PharmacogenomicsAutores:Adrián LLerena, Berecz R., Cáceres M.C., Dorado P., Penãs-Lledó E.M.Fuentes:scopus